Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Receivables (2018 - 2025)

TransMedics (TMDX) has 8 years of Change in Receivables data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 54.32% year-over-year to $3.6 million; the TTM value through Dec 2025 reached -$14.0 million, down 140.66%, while the annual FY2025 figure was -$14.0 million, 140.66% down from the prior year.
  • Change in Receivables reached $3.6 million in Q4 2025 per TMDX's latest filing, up from -$24.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $44.1 million in Q1 2025 and bottomed at -$37.5 million in Q2 2025.
  • Average Change in Receivables over 5 years is $3.8 million, with a median of $4.5 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: skyrocketed 895.54% in 2022, then tumbled 4856.14% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $1.8 million in 2021, then soared by 197.85% to $5.4 million in 2022, then tumbled by 47.71% to $2.8 million in 2023, then surged by 178.15% to $7.8 million in 2024, then tumbled by 54.32% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $3.6 million in Q4 2025, -$24.1 million in Q3 2025, and -$37.5 million in Q2 2025.